MDM2 and cancer: While some cancers acquire amplification or overexpression of PHGDH, the first and rate-limiting step in this pathway, other types of cancers activate oncogenes such as MYC, MDM2, KRAS, and NRF2, leading to increased SSP enzyme expression (19, 23–26).